Dynavax Technologies Corporation
Dynavax Technologies is a biopharmaceutical company dedicated to developing and commercializing novel vaccines to help protect the world against infectious diseases, utilizing proven, innovative adjuvant technology. They focus on developing vaccines like HEPLISAV-B® for hepatitis B and have a broad pipeline of vaccines to prevent infectious diseases.
Industries
Nr. of Employees
large (251-1000)
Dynavax Technologies Corporation
Eichsfelder Strasse 11, D-40595 Düsseldorf, Germany
Patents
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11981670-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11124510-B2
View Details
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11981670-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11124510-B2
View DetailsProducts
HEPLISAV-B (hepatitis B vaccine, recombinant, adjuvanted)
Recombinant hepatitis B vaccine formulated with a TLR9‑targeting oligonucleotide adjuvant for prevention of hepatitis B virus infection in adults.
CpG 1018 adjuvant (TLR9 agonist)
A clinically studied synthetic CpG oligonucleotide adjuvant that targets TLR9 to enhance antibody and T‑cell responses; used in licensed hepatitis B vaccine and made available for partner development programs.
HEPLISAV-B (hepatitis B vaccine, recombinant, adjuvanted)
Recombinant hepatitis B vaccine formulated with a TLR9‑targeting oligonucleotide adjuvant for prevention of hepatitis B virus infection in adults.
CpG 1018 adjuvant (TLR9 agonist)
A clinically studied synthetic CpG oligonucleotide adjuvant that targets TLR9 to enhance antibody and T‑cell responses; used in licensed hepatitis B vaccine and made available for partner development programs.
Services
Partnerships to provide a clinically studied TLR9 oligonucleotide adjuvant to research institutions and vaccine developers for use in adjuvanted vaccine programs.
Manufacturing services including recombinant antigen production, process development, GMP production, and transfer of manufacturing technologies to partner facilities.
Design and execution of clinical trials for vaccine candidates, including observer‑blinded, randomized and controlled Phase 1/2 and Phase 2 studies.
Partnerships to provide a clinically studied TLR9 oligonucleotide adjuvant to research institutions and vaccine developers for use in adjuvanted vaccine programs.
Manufacturing services including recombinant antigen production, process development, GMP production, and transfer of manufacturing technologies to partner facilities.
Design and execution of clinical trials for vaccine candidates, including observer‑blinded, randomized and controlled Phase 1/2 and Phase 2 studies.
Expertise Areas
- Vaccine research and development
- Adjuvant discovery and development (TLR‑targeted)
- Clinical trial management
- GMP manufacturing and CMC
Key Technologies
- Toll-like receptor (TLR) agonists (TLR9; TLR7/TLR8)
- Synthetic CpG oligonucleotides (TLR9 agonists)
- Yeast-based recombinant protein expression (Hansenula polymorpha)
- Adjuvant formulation and nanoparticle conjugates